Track Day One Biopharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Day One Biopharmaceuticals, Inc. DAWN · Stock Open Day One Biopharmaceuticals, Inc. in new tab

21.53 USD
EPS
-1.04
P/B
5.03
ROE
-22.74
Beta
-1.75
Loading chart...
Key Metrics
Earnings dateMay 13, 2026
EPS-1.04
Book Value4.28
Price to Book5.03
Debt/Equity0.63
% Insiders16.821%
Growth
Revenue Growth0.84%
Estimates
Forward P/E-504.10
Forward EPS-0.19

DCF valuation

Model fair value for Day One Biopharmaceuticals, Inc. (DAWN)
Result
Sign in to run the valuation for DAWN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Day One Biopharmaceuticals, Inc. Logo Day One Biopharmaceuticals, Inc. Analysis (DAWN)

United States Financials Official Website Stock

Is Day One Biopharmaceuticals, Inc. a good investment? Day One Biopharmaceuticals, Inc. (DAWN) is currently trading at 21.53 USD.

Earnings Schedule: Day One Biopharmaceuticals, Inc. is expected to release its next earnings report on May 13, 2026. The market consensus estimate for Forward EPS is -0.19.

Investor FAQ

Does Day One Biopharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Day One Biopharmaceuticals, Inc.?

Day One Biopharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 13, 2026. The company currently has a trailing EPS of -1.04.

Company Profile

Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. As of April 22, 2026, Day One Biopharmaceuticals, Inc. operates as a subsidiary of Servier Pharmaceuticals LLC.

Exchange Ticker
NMS (United States) DAWN
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion